We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Taste and Palatability of Orfadin Suspension

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01734889
First Posted: November 28, 2012
Last Update Posted: November 6, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Swedish Orphan Biovitrum
  Purpose
The purpose of this study is to verify that pediatric patients, especially those who are not old enough to swallow capsules, accept the taste and palatability of a new suspension.

Condition Intervention Phase
Hereditary Tyrosinemia, Type I Drug: Nitisinone Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Taste and Palatability of Orfadin Suspension. An Open, Non-controlled 3 Day Study in Pediatric Patients With Hereditary Tyrosinemia Type 1 Treated With Orfadin.

Resource links provided by NLM:


Further study details as provided by Swedish Orphan Biovitrum:

Primary Outcome Measures:
  • The Taste Score for the Last Dose of the Suspension on Day 3 for Subjects 5 - <18 Years [ Time Frame: Day 3 ]
    Patients rated the taste of the suspension. The following grading was applied: 5 (very good taste), 4 (good taste), 3 (neither good nor bad taste), 2 (bad taste) and 1 (very bad taste).

  • The Acceptability Score for the Last Dose of the Suspension on Day 3 for Subjects < 5 Years [ Time Frame: Day 3 ]
    The parents of patients aged <5 years rated their child´s acceptability of the suspension. The following grading was applied: 5 (very well), 4 (well), 3 (neither well nor badly), 2 (badly) and 1 (very badly).


Secondary Outcome Measures:
  • The Palatability Scores on Day 1 (Subjects 5 - < 18 Years) [ Time Frame: Day 1 ]
    Patients rated the palatability of the suspension. The following grading was applied: 5 (very good), 4 (good), 3 (neither good nor bad), 2 (bad) and 1 (very bad).

  • The Palatability Scores on Day 2 (Subjects 5 - < 18 Years) [ Time Frame: Day 2 ]
    Patients rated the palatability of the suspension. The following grading was applied: 5 (very good), 4 (good), 3 (neither good nor bad), 2 (bad) and 1 (very bad).

  • The Palatability Scores on Day 3 (Subjects 5 - < 18 Years) [ Time Frame: Day 3 ]
    Patients rated the palatability of the suspension. The following grading was applied: 5 (very good), 4 (good), 3 (neither good nor bad), 2 (bad) and 1 (very bad).


Enrollment: 18
Study Start Date: October 2012
Study Completion Date: March 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Orfadin suspension
Drug: nitisinone, oral suspension
Drug: Nitisinone
Oral suspension

Detailed Description:

This is an open, non-randomized, non-controlled, multiple-dose study in 18 pediatric patients. The treatment period is three days, and during the study the subjects will rate the taste and palatability of the suspension or (for younger children) their parents will rate the child´s acceptance of the suspension.

The study consists of a screening period, a 3 day treatment period and a 1 week follow-up period.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   1 Month to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with HT-1 currently managed on Orfadin (nitisinone) capsules.
  • Age from 1 month to less than 18 years.
  • Signed informed consent.

Exclusion Criteria:

  • Any medical condition which in the opinion of the investigator makes the subject unsuitable for inclusion.
  • Enrollment in another concurrent clinical study, or intake of an investigational medicinal product (IMP), within one month prior to inclusion in this study.
  • Foreseeable inability to cooperate with given instructions or study procedures.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01734889


Locations
France
Hopital Necker
Paris, France
Germany
Universitätsklinikum Düsseldorf
Düsseldorf, Germany
Universitätsklinikum Heidelberg
Heidelberg, Germany
Klinikum der Universität München
München, Germany
United Kingdom
Birmingham Children's Hospital
Birmingham, United Kingdom
Evelina Children's Hospital, St Thomas' Hospital
London, United Kingdom
St Mary's Hospital
Manchester, United Kingdom
Sponsors and Collaborators
Swedish Orphan Biovitrum
Investigators
Study Director: Erik Brouwer, MD Swedish Orphan Biovitrum
  More Information

Responsible Party: Swedish Orphan Biovitrum
ClinicalTrials.gov Identifier: NCT01734889     History of Changes
Other Study ID Numbers: Sobi.NTBC-002
First Submitted: November 22, 2012
First Posted: November 28, 2012
Results First Submitted: January 21, 2014
Results First Posted: March 4, 2014
Last Update Posted: November 6, 2014
Last Verified: October 2014

Keywords provided by Swedish Orphan Biovitrum:
nitisinone
Orfadin
suspension
taste
acceptability

Additional relevant MeSH terms:
Tyrosinemias
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Amino Acid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases
Nitisinone
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action